BRPI0917853A2 - composição farmacêutica, polímero reticulado de troca catiônica ou uma composição farmacêutica para remover potássio do trato gastrointestinal, polímetro carboxílico alifático reticulado estabilizado de poliol linear, e, método para fazer um polímetro reticulado de troca catiônica - Google Patents

composição farmacêutica, polímero reticulado de troca catiônica ou uma composição farmacêutica para remover potássio do trato gastrointestinal, polímetro carboxílico alifático reticulado estabilizado de poliol linear, e, método para fazer um polímetro reticulado de troca catiônica

Info

Publication number
BRPI0917853A2
BRPI0917853A2 BRPI0917853A BRPI0917853A BRPI0917853A2 BR PI0917853 A2 BRPI0917853 A2 BR PI0917853A2 BR PI0917853 A BRPI0917853 A BR PI0917853A BR PI0917853 A BRPI0917853 A BR PI0917853A BR PI0917853 A2 BRPI0917853 A2 BR PI0917853A2
Authority
BR
Brazil
Prior art keywords
cross
pharmaceutical composition
cation exchange
linked
polymer
Prior art date
Application number
BRPI0917853A
Other languages
English (en)
Inventor
Detlef Albrecht
Dominique Charmot
Eric Connor
Han-Ting Chang
I-Zu Huang
Jonathan Mills
Michael Burdick
Mingjun Liu
Paul Mansky
Ramakrishnan Chidambaram
Sherin Halfon
WERNER STRüVER
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917853(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of BRPI0917853A2 publication Critical patent/BRPI0917853A2/pt
Publication of BRPI0917853B1 publication Critical patent/BRPI0917853B1/pt
Publication of BRPI0917853B8 publication Critical patent/BRPI0917853B8/pt
Publication of BRPI0917853C1 publication Critical patent/BRPI0917853C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
BRPI0917853A 2008-08-22 2009-08-22 polímero reticulado de troca catiônica BRPI0917853C1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9111008P 2008-08-22 2008-08-22
US9112508P 2008-08-22 2008-08-22
US9109708P 2008-08-22 2008-08-22
US16589909P 2009-04-01 2009-04-01
US16589409P 2009-04-01 2009-04-01
US16590509P 2009-04-02 2009-04-02
PCT/US2009/054706 WO2010022383A2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Publications (4)

Publication Number Publication Date
BRPI0917853A2 true BRPI0917853A2 (pt) 2015-11-24
BRPI0917853B1 BRPI0917853B1 (pt) 2020-04-07
BRPI0917853B8 BRPI0917853B8 (pt) 2020-04-22
BRPI0917853C1 BRPI0917853C1 (pt) 2021-05-25

Family

ID=41707686

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917853A BRPI0917853C1 (pt) 2008-08-22 2009-08-22 polímero reticulado de troca catiônica

Country Status (26)

Country Link
US (4) US20110236340A1 (pt)
EP (4) EP2957286B1 (pt)
JP (7) JP5756403B2 (pt)
KR (5) KR101825113B1 (pt)
CN (2) CN103919792B (pt)
AU (1) AU2009282721B2 (pt)
BR (1) BRPI0917853C1 (pt)
CA (1) CA2735058C (pt)
CY (3) CY2018002I1 (pt)
DE (1) DE112009002063T5 (pt)
DK (3) DK2365988T4 (pt)
ES (4) ES3034535T3 (pt)
FI (1) FI3431094T3 (pt)
GB (4) GB2495427B (pt)
HR (4) HRP20230091T1 (pt)
HU (4) HUE025934T2 (pt)
LT (4) LT2957286T (pt)
LU (1) LUC00094I2 (pt)
MX (3) MX2011001893A (pt)
NL (1) NL300962I2 (pt)
NO (2) NO2018004I1 (pt)
PL (4) PL2365988T5 (pt)
PT (3) PT3431094T (pt)
SI (2) SI3431094T1 (pt)
SM (2) SMT201800660T1 (pt)
WO (1) WO2010022383A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574716B2 (en) * 2006-01-23 2013-11-05 Hitachi Chemical Co., Ltd. Ionic polymer devices and methods of fabricating the same
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
ES3034535T3 (en) 2008-08-22 2025-08-19 Vifor Int Ltd Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2011119422A1 (en) 2010-03-20 2011-09-29 Relypsa, Inc. Continuous process for preparing polyfluoroacrylate particles
HRP20190146T4 (hr) 2011-02-11 2025-11-07 Zs Pharma, Inc Uporaba cirkonijevog silikata za liječenje hiperkalemije
ES2758708T3 (es) 2011-06-27 2020-05-06 Relypsa Inc Fluoración de ésteres de acrilato y derivados
US9453092B2 (en) 2011-06-27 2016-09-27 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid
MX2015000810A (es) * 2012-07-19 2015-06-05 Relypsa Inc Composiciones que comprenden polímeros reticulados con enlace a cationes.
JP6115973B2 (ja) * 2012-08-09 2017-04-19 パセオン オーストリア ゲーエムベーハー ウント ツェーオー カーゲー ポリマー材料の乾燥方法
JP6475624B2 (ja) * 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
US20160051584A1 (en) 2013-04-05 2016-02-25 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
RU2017126229A (ru) * 2014-12-23 2019-01-28 Арделикс, Инк. Композиции и способы лечения гиперкалиемии
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
WO2019220450A1 (en) 2018-05-16 2019-11-21 Solara Active Pharma Sciences Limited Process for preparation of patiromer
WO2020182927A1 (en) * 2019-03-13 2020-09-17 Astrazeneca Ab Potassium-binding agents for use in hemodialysis patients
US12441677B2 (en) 2019-11-14 2025-10-14 Vifor (International) Ltd. One step synthesis for alkyl 2-fluoroacrylates
US12522682B2 (en) 2020-03-27 2026-01-13 Vifor (International) Ltd. Synthesis of methyl 2-fluoroacrylate
EP4171582B1 (en) * 2021-09-13 2024-03-13 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymer medicament for treating hyperkalemia and preparation method thereof
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN114369729B (zh) * 2021-12-28 2023-11-03 江苏容汇通用锂业股份有限公司 一种利用锂矿渣进行浸出液除钾的工艺
CN114394918B (zh) * 2022-01-19 2023-10-20 罗长青 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
NL137053C (pt) 1967-01-30
FR2171934B1 (pt) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
DE2846187A1 (de) 1978-10-24 1980-05-08 Bayer Ag Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) † 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
EP0565086B1 (en) 1992-04-10 1996-12-27 Mitsubishi Chemical Corporation Method for producing a spherical acrylonitrile crosslinked copolymer
NZ255758A (en) * 1992-08-20 1997-10-24 Du Pont Crosslinked polymeric ammonium salts useful as bile sequestrants
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH09506342A (ja) * 1993-11-25 1997-06-24 サルテルナテ・ベー・ブイ 一価カチオンに結合する粒子、並びにナトリウムおよび／またはカリウムイオンを捕捉して除去するための上記粒子の使用および方法
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
DE19951116A1 (de) 1999-10-23 2001-04-26 Bosch Gmbh Robert Relais, insbesondere für eine Startvorrichtung
DE19962935A1 (de) † 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen
EP1249240A4 (en) * 2000-01-14 2003-03-19 Otsuka Pharma Co Ltd INHIBITORS OF SODIUM ION ABSORPTION, AND PROPHYLACTIC OR THERAPEUTIC AGENTS AND FOOD PRODUCTS CONTAINING SAID INHIBITORS
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
WO2002009734A1 (en) * 2000-08-01 2002-02-07 Oryza Oil & Fat Chemical Co.,Ltd. Sugar absorption inhibitors and process for producing the same
DE60132256T2 (de) * 2000-11-20 2008-12-24 Sorbent Therapeutics, Inc., Vernon Hills Wasserabsorbierende polymere und deren verwendung
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
EP1596955A1 (en) * 2003-02-25 2005-11-23 Finnfeeds Finland OY A simulated moving bed system and process
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
KR101228233B1 (ko) * 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
DE112006002618T5 (de) * 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
BRPI0616603A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN101835500B (zh) * 2007-08-29 2014-05-28 吸附剂治疗学公司 具有可变抗衡离子含量的吸收性聚合物组合物及其制备方法和用途
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
ES3034535T3 (en) 2008-08-22 2025-08-19 Vifor Int Ltd Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties

Also Published As

Publication number Publication date
CN103919792B (zh) 2018-03-09
JP2020172537A (ja) 2020-10-22
SMT201500207T1 (it) 2015-10-30
GB201222750D0 (en) 2013-01-30
HK1184675A1 (en) 2014-01-30
GB2495426A (en) 2013-04-10
JP2014144978A (ja) 2014-08-14
JP2012500806A (ja) 2012-01-12
NO2018004I1 (no) 2018-01-17
GB2475657A (en) 2011-05-25
GB2495427A (en) 2013-04-10
LTC2957286I2 (lt) 2019-11-25
KR101825113B1 (ko) 2018-02-02
EP2365988B1 (en) 2015-07-22
KR20180014845A (ko) 2018-02-09
KR20110063647A (ko) 2011-06-13
US20220000906A1 (en) 2022-01-06
JP2014144977A (ja) 2014-08-14
PT2365988E (pt) 2015-10-22
GB2475657B (en) 2013-05-29
PL2957286T3 (pl) 2019-03-29
EP4201408A1 (en) 2023-06-28
EP4201408C0 (en) 2025-06-25
ES2939021T3 (es) 2023-04-18
HUS1900003I1 (hu) 2019-02-28
CN103919792A (zh) 2014-07-16
PL3431094T3 (pl) 2023-04-24
CN102202670A (zh) 2011-09-28
PL2365988T5 (pl) 2019-11-29
EP2365988B2 (en) 2019-07-03
KR102150184B1 (ko) 2020-08-31
HRP20230091T1 (hr) 2023-03-17
KR20200029614A (ko) 2020-03-18
ES3034535T3 (en) 2025-08-19
CY2018002I1 (el) 2019-07-10
JP5883471B2 (ja) 2016-03-15
AU2009282721A1 (en) 2010-02-25
JP6232468B2 (ja) 2017-11-15
JP6633583B2 (ja) 2020-01-22
KR101928973B1 (ko) 2018-12-13
DK2365988T4 (da) 2019-10-07
PT3431094T (pt) 2023-03-03
AU2009282721B2 (en) 2015-10-29
LT3431094T (lt) 2023-02-27
GB201222749D0 (en) 2013-01-30
ES2545887T5 (es) 2020-02-17
BRPI0917853B1 (pt) 2020-04-07
HUE071829T2 (hu) 2025-09-28
NL300962I1 (nl) 2018-12-28
GB201222752D0 (en) 2013-01-30
HUE025934T2 (en) 2016-05-30
GB2495427B (en) 2013-08-07
KR102178208B1 (ko) 2020-11-12
GB2495428A (en) 2013-04-10
CY1120930T1 (el) 2020-05-29
LUC00094I1 (pt) 2018-12-19
JP2019065030A (ja) 2019-04-25
JP5756403B2 (ja) 2015-07-29
EP3431094B1 (en) 2022-12-07
ES2699494T3 (es) 2019-02-11
DK2957286T3 (en) 2018-12-17
BRPI0917853B8 (pt) 2020-04-22
PL4201408T3 (pl) 2025-09-22
KR102300471B1 (ko) 2021-09-30
DK3431094T3 (da) 2023-02-20
NO2018041I1 (pt) 2018-12-14
CN102202670B (zh) 2014-04-30
LUC00094I2 (pt) 2020-01-23
KR20180133561A (ko) 2018-12-14
PL2365988T3 (pl) 2015-12-31
FI3431094T3 (fi) 2023-03-20
HRP20250774T1 (hr) 2025-08-29
NL300962I2 (nl) 2020-06-02
EP2365988A2 (en) 2011-09-21
WO2010022383A3 (en) 2010-09-23
SMT201800660T1 (it) 2019-01-11
EP2957286A1 (en) 2015-12-23
BRPI0917853C1 (pt) 2021-05-25
MX389664B (es) 2025-03-20
HRP20181961T1 (hr) 2019-02-08
CA2735058A1 (en) 2010-02-25
EP3431094A1 (en) 2019-01-23
ES2545887T3 (es) 2015-09-16
LTPA2018016I1 (lt) 2019-01-10
HRP20150955T1 (hr) 2015-10-09
KR20200128600A (ko) 2020-11-13
JP2016145256A (ja) 2016-08-12
HUE061320T2 (hu) 2023-06-28
US20200289550A1 (en) 2020-09-17
EP4201408B1 (en) 2025-06-25
PT2957286T (pt) 2018-11-30
LTPA2018004I1 (lt) 2018-02-12
SI2957286T1 (sl) 2018-12-31
CY2019002I1 (el) 2020-05-29
DE112009002063T5 (de) 2012-01-12
US20110236340A1 (en) 2011-09-29
DK2365988T3 (en) 2015-10-26
EP2957286B1 (en) 2018-11-21
JP6890116B2 (ja) 2021-06-18
MX364398B (es) 2019-04-24
WO2010022383A2 (en) 2010-02-25
SI3431094T1 (sl) 2023-04-28
LT2957286T (lt) 2018-12-10
US20170165292A1 (en) 2017-06-15
MX2011001893A (es) 2011-09-27
CY2019002I2 (el) 2020-05-29
GB201104561D0 (en) 2011-05-04
JP2017218454A (ja) 2017-12-14
CA2735058C (en) 2021-01-26

Similar Documents

Publication Publication Date Title
BRPI0917853A2 (pt) composição farmacêutica, polímero reticulado de troca catiônica ou uma composição farmacêutica para remover potássio do trato gastrointestinal, polímetro carboxílico alifático reticulado estabilizado de poliol linear, e, método para fazer um polímetro reticulado de troca catiônica
BRPI0815708A2 (pt) Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0907548A2 (pt) Sistema e método de rastreamento da zona dental para uma escova de dentes
BRPI0917553A2 (pt) método e sistema para extração de gás carbônico por antisublimação sob pressão aumentada
BRPI0807756A2 (pt) Método para produzir um l-aminoácido.
BRPI0924609A2 (pt) um método e um sistema para mudança de uma trajetória do veículo
BRPI1009390A2 (pt) "método e aparelho de associação e manutenção da informação de estado para aplicações."
BRPI0819117A2 (pt) sistema de dispensação de composição de combustível, e, método para fornecer uma composição de combustível
BRPI0813429A2 (pt) sistema e método para uma mbms aperfeiçoada para uma transferência de pss
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0817672A2 (pt) Método e aparelho para produção de ácido acético com purificação aperfeiçoada
BRPI0912830A2 (pt) aparelho e método para aliviar obstrução de uma via aérea
FR2914180B1 (fr) Cage expansive pour chirurgie vertebrale.
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0813146A2 (pt) Método para operar uma instalação de gado, método para controlar gado, e, sistema de processamento de gado
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0717408A2 (pt) Método de estimativa de força para um sistema médico minimamente invasivo
BR112012002308A2 (pt) dispositivo e método para detectar uma molécula alvo, sistema, e, kit
BRPI0917168A2 (pt) sistema e método para detectar uma câmera
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0921659A2 (pt) metodo e sistema para formar uma protese dentaria
BRPI0719784A2 (pt) Processo para preparação de aidas terciárias de ácidos alquilfenilcarboxílicos
BRPI0916167A2 (pt) "método para remover contaminantes de caroços de cacau, licor de cacau, produto alimentício e sistema para produzir uma composição contendo cacau"
BRPI0810724A2 (pt) Método e sistema para extrair e separar um soluto de uma composição insolúvel.
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2570 DE 07/04/2020 QUANTO AO TITULO E PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: VIFOR ( INTERNATIONAL ) AG (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: RELYPSA,INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2641 DE 17/08/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: VIFOR (INTERNATIONAL) LTD. (CH)

B25A Requested transfer of rights approved

Owner name: VIFOR PHARMA TECHNOLOGY AG (CH)

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067552, DE 26/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI

B25A Requested transfer of rights approved

Owner name: VIFOR (INTERNATIONAL) LTD. (CH)